Protocols
BMTCTN-1904 Phase II OPEN TO ACCRUAL
BMTCTN-1904 Hematopoietic Cell Transplantation Using Treosulfan-Based Conditioning for the Treatment of Bone Marrow Failure Diseases
COG-ANHL1522 Phase II OPEN TO ACCRUAL *
A Pilot Study of Rituximab (RTX) and Third Party Latent Membrane Protein (LMP)-specific Cytotoxic T-Lymphocytes (LMP-TC, IND # 17068) in Pediatric Solid Organ Recipients (SOT) with EBV-Positive CD20-Positive Post-Transplant Lymphoproliferative Disease (PTLD)
IIT-TALANO-CART-ALL Phase I OPEN TO ACCRUAL
Phase 1 Study of Redirected Autologous T Cells Engineered to Contain an Anti-CD19 and Anti-CD20 scFv Coupled to CD3-zeta; and 4-1BB Signaling Domains in Pediatric and Young Adult Patients with Relapsed and/or Refractory CD19 or CD20 B-cell Acute Lymphoblastic Leukemia
PBMTC-ONC1401 Phase II OPEN TO ACCRUAL
The Role of KIR-favorably Mismatched Haploidentical Transplantation and KIR-polymorphisms in Determining Outcomes of Children with ALL/AML/MDS Undergoing Allogeneic Hematopoietic Cell Transplantation
PIDTC-CSIDE Phase II OPEN TO ACCRUAL *
A randomized trial of low versus moderate exposure busulfan for infants with severe combined immunodeficiency (SCID) receiving TCR alpha beta+/CD19+ depleted transplantation: A Phase II study by the Primary Immune Deficiency Treatment Consortium (PIDTC) and Pediatric Blood and Marrow Transplant Consortium (PBMTC) PIDTC CSIDE Protocol (Conditioning SCID Infants Diagnosed Early) PBMTC NMD 1801
PTCTC-ONC1701-ENDRAD Phase II OPEN TO ACCRUAL
A Phase II Pilot Trial to Estimate Survival after a Non-total Body Irradiation (TBI) Based Conditioning Regimen in Patients Diagnosed with B-acute Lymphoblastic Leukemia (ALL) Who are Pre-allogeneic Hematopoietic Cell Transplantation (HCT) Next-generation-sequence (NGS) Minimal Residual Disease (MRD) Negative